Therefore, we focused on HIF-1α as a promising key player in IP-mediated lung cancer progression and tumor microenvironmental changes, and demonstrated that a HIF-1α inhibitor was effective against lung cancer with IP. The gene discussed is HIF1A; the disease is neoplasm.